Cytori Therapeutics Company Profile (NASDAQ:CYTX)

About Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics logoCytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient's own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CYTX
  • CUSIP: 23283K10
  • Web: www.cytori.com
Capitalization:
  • Market Cap: $24.48 million
  • Outstanding Shares: 23,568,000
Average Prices:
  • 50 Day Moving Avg: $1.06
  • 200 Day Moving Avg: $1.48
  • 52 Week Range: $0.90 - $3.12
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.29
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $10.07 million
  • Price / Sales: 2.41
  • Book Value: $0.31 per share
  • Price / Book: 3.32
Profitability:
  • EBIDTA: ($18,720,000.00)
  • Net Margins: -314.07%
  • Return on Equity: -172.63%
  • Return on Assets: -60.18%
Debt:
  • Debt-to-Equity Ratio: 0.89%
  • Current Ratio: 1.93%
  • Quick Ratio: 1.57%
Misc:
  • Average Volume: 775,906 shs.
  • Beta: 2.69
  • Short Ratio: 1.99
 

Frequently Asked Questions for Cytori Therapeutics (NASDAQ:CYTX)

What is Cytori Therapeutics' stock symbol?

Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."

When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?

Cytori Therapeutics's stock reverse split before market open on Thursday, May 12th 2016. The 1-15 reverse split was announced on Thursday, May 12th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 11th 2016. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 7 shares after the split.

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) released its quarterly earnings results on Thursday, May, 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.05. The business had revenue of $0.60 million for the quarter, compared to analysts' expectations of $2.32 million. Cytori Therapeutics had a negative net margin of 314.07% and a negative return on equity of 172.63%. The company's quarterly revenue was down 53.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.03) EPS. View Cytori Therapeutics' Earnings History.

Where is Cytori Therapeutics' stock going? Where will Cytori Therapeutics' stock price be in 2017?

3 equities research analysts have issued 1 year price objectives for Cytori Therapeutics' stock. Their predictions range from $2.30 to $11.00. On average, they expect Cytori Therapeutics' stock price to reach $7.77 in the next year. View Analyst Ratings for Cytori Therapeutics.

What are analysts saying about Cytori Therapeutics stock?

Here are some recent quotes from research analysts about Cytori Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (5/12/2017)
  • 2. Maxim Group analysts commented, "With the closure of the Azaya acquisition announced this morning, we now assume a 15% market share and 35% royalty rate for the $300M European Liposomal Doxorubicin market with the first year of commercial sales in 2019. We recognize that a US fast track strategy could put Cytori's Doxorubicin in the US market (even before Europe) but for conservatism we do not assume US revenues in our model (nor do we assume Japan, or any other geographies which will likely evolve as well). We believe our 15% share and 35% royalty rates are both realistic (and market share could be conservative). The result of these changes is our valuation target now changes from $6 to $10 per share." (2/15/2017)

Are investors shorting Cytori Therapeutics?

Cytori Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totalling 1,232,942 shares, an increase of 51.2% from the April 28th total of 815,360 shares. Based on an average daily trading volume, of 315,749 shares, the days-to-cover ratio is presently 3.9 days. Currently, 4.5% of the shares of the stock are sold short.

Who are some of Cytori Therapeutics' key competitors?

Who owns Cytori Therapeutics stock?

Cytori Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (5.39%), Perkins Capital Management Inc. (1.87%), Vanguard Group Inc. (1.43%) and Creative Planning (0.33%). Company insiders that own Cytori Therapeutics stock include David Rickey, Gail K Naughton, Jeremy B Hayden, John David Harris, Marc H Hedrick, Steven Kesten, Tiago Girao and Tommy G Thompson. View Institutional Ownership Trends for Cytori Therapeutics.

Who sold Cytori Therapeutics stock? Who is selling Cytori Therapeutics stock?

Cytori Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Cytori Therapeutics.

Who bought Cytori Therapeutics stock? Who is buying Cytori Therapeutics stock?

Cytori Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Perkins Capital Management Inc. and Creative Planning. Company insiders that have bought Cytori Therapeutics stock in the last two years include David Rickey, Gail K Naughton, Jeremy B Hayden, John David Harris, Marc H Hedrick, Steven Kesten, Tiago Girao and Tommy G Thompson. View Insider Buying and Selling for Cytori Therapeutics.

How do I buy Cytori Therapeutics stock?

Shares of Cytori Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cytori Therapeutics stock cost?

One share of Cytori Therapeutics stock can currently be purchased for approximately $1.03.

Analyst Ratings

Consensus Ratings for Cytori Therapeutics (NASDAQ:CYTX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.77 (654.05% upside)

Analysts' Ratings History for Cytori Therapeutics (NASDAQ:CYTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017B. RileyReiterated RatingBuy$2.30HighView Rating Details
5/13/2017Maxim GroupSet Price TargetBuy$10.00MediumView Rating Details
6/28/2016Roth CapitalReiterated RatingBuy$11.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Cytori Therapeutics (NASDAQ:CYTX)
Earnings by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Earnings History by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.31)($0.26)$2.32 million$0.60 millionViewN/AView Earnings Details
3/23/2017Q4 16($0.23)($0.24)$3.36 million$1.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.24)($0.26)$2.85 million$2.61 millionViewListenView Earnings Details
8/4/2016Q216($0.39)($0.43)$2.50 million$1.10 millionViewN/AView Earnings Details
5/10/2016Q1($0.03)($0.41)$2.05 million$2.90 millionViewListenView Earnings Details
3/3/2016Q4($0.04)($0.03)$2.90 million$1.56 millionViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.04)$5.27 million$2.48 millionViewN/AView Earnings Details
8/6/2015Q215($0.03)($0.03)$2.50 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.07)$2.44 million$0.90 millionViewListenView Earnings Details
3/12/2015Q4 14($0.08)($0.08)$3.10 million$2.47 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.09)($0.12)$4.31 million$1.10 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.11)($0.15)$2.76 million$0.94 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.14)$2.87 million$1.03 millionViewN/AView Earnings Details
3/12/2014Q413($0.12)($0.14)$4.37 million$2.71 millionViewN/AView Earnings Details
11/7/2013Q313($0.11)($0.08)$3.17 million$8.70 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.13)($0.16)$2.88 million$6.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.16)($0.11)ViewN/AView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.25 million$1.31 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cytori Therapeutics (NASDAQ:CYTX)
2017 EPS Consensus Estimate: ($0.77)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.30)($0.30)($0.30)
Q2 20171($0.25)($0.25)($0.25)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytori Therapeutics (NASDAQ:CYTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cytori Therapeutics (NASDAQ:CYTX)
Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 14.17%
Insider Trades by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Institutional Ownership by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Insider Trades by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2016John David HarrisVPBuy2,500$2.03$5,075.00View SEC Filing  
6/14/2016Gail K NaughtonDirectorBuy1,000$2.10$2,100.00View SEC Filing  
5/13/2016John David HarrisVPBuy2,000$2.71$5,420.00View SEC Filing  
3/9/2016David RickeyDirectorBuy150,000$0.19$28,500.00View SEC Filing  
9/3/2015Tommy G ThompsonDirectorBuy25,449$0.37$9,416.13View SEC Filing  
9/2/2015Jeremy B HaydenVPBuy8,200$0.36$2,952.00View SEC Filing  
8/28/2015David RickeyDirectorBuy56,000$0.31$17,360.00View SEC Filing  
8/28/2015Marc H HedrickCEOBuy11,200$0.31$3,472.00View SEC Filing  
8/27/2015David RickeyDirectorBuy75,000$0.31$23,250.00View SEC Filing  
8/21/2015David RickeyDirectorBuy50,000$0.38$19,000.00View SEC Filing  
8/21/2015Marc H HedrickCEOBuy5,000$0.38$1,900.00View SEC Filing  
8/20/2015Marc H HedrickCEOBuy10,000$0.40$4,000.00View SEC Filing  
8/19/2015David RickeyDirectorBuy48,600$0.39$18,954.00View SEC Filing  
8/19/2015Steven KestenVPBuy6,000$0.39$2,340.00View SEC Filing  
8/18/2015David RickeyDirectorBuy51,400$0.39$20,046.00View SEC Filing  
8/18/2015Marc H HedrickCEOBuy10,000$0.39$3,900.00View SEC Filing  
8/18/2015Tiago GiraoCFOBuy25,000$0.39$9,750.00View SEC Filing  
11/13/2014David RickeyDirectorBuy20,000$0.47$9,400.00View SEC Filing  
11/12/2014David RickeyDirectorBuy200,000$0.39$78,000.00View SEC Filing  
11/12/2014Tiago GiraoCFOBuy60,000$0.39$23,400.00View SEC Filing  
11/11/2014Tiago GiraoCFOBuy15,889$0.39$6,196.71View SEC Filing  
6/5/2014David RickeyDirectorBuy30,000$2.34$70,200.00View SEC Filing  
9/12/2013David RickeyDirectorBuy7,100$2.55$18,105.00View SEC Filing  
9/11/2013David RickeyDirectorBuy2,000$2.58$5,160.00View SEC Filing  
9/9/2013David RickeyDirectorBuy5,000$2.31$11,550.00View SEC Filing  
9/5/2013David RickeyDirectorBuy2,000$2.24$4,480.00View SEC Filing  
9/3/2013David RickeyDirectorBuy7,000$2.14$14,980.00View SEC Filing  
8/30/2013Tommy G ThompsonDirectorBuy5,000$2.14$10,700.00View SEC Filing  
12/19/2012Lloyd H DeanDirectorBuy25,000$2.85$71,250.00View SEC Filing  
12/19/2012Marc H HedrickPresidentBuy10,000$2.85$28,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cytori Therapeutics (NASDAQ:CYTX)
Latest Headlines for Cytori Therapeutics (NASDAQ:CYTX)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Cytori Therapeutics, Inc. : May 25, 2017
finance.yahoo.com - May 25 at 6:25 PM
finance.yahoo.com logoCytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 12:38 PM
finance.yahoo.com logoCytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial
finance.yahoo.com - May 23 at 12:32 PM
finance.yahoo.com logoCytori Provides Latest Corporate Update at the 18th Annual B. Riley & Co. Institutional Investor Conference
finance.yahoo.com - May 16 at 12:06 PM
americanbankingnews.com logoFY2019 EPS Estimates for Cytori Therapeutics Inc Lowered by B. Riley (CYTX)
www.americanbankingnews.com - May 15 at 10:10 AM
americanbankingnews.com logoB. Riley Reaffirms "Buy" Rating for Cytori Therapeutics Inc (CYTX)
www.americanbankingnews.com - May 14 at 10:14 PM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) Sees Significant Drop in Short Interest
www.americanbankingnews.com - May 13 at 7:44 AM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 12 at 7:41 PM
finance.yahoo.com logoEdited Transcript of CYTX earnings conference call or presentation 11-May-17 9:30pm GMT
finance.yahoo.com - May 12 at 5:10 PM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) Issues Earnings Results
www.americanbankingnews.com - May 12 at 3:12 PM
americanbankingnews.com logoQ1 2017 Earnings Estimate for Cytori Therapeutics Inc (CYTX) Issued By B. Riley
www.americanbankingnews.com - May 12 at 7:48 AM
rttnews.com logoEARNINGS SUMMARY: Details of Cytori Therapeutics Inc. Q1 Earnings Report
www.rttnews.com - May 11 at 10:18 PM
finance.yahoo.com logoCytori reports 1Q loss
finance.yahoo.com - May 11 at 10:18 PM
finance.yahoo.com logoCytori Reports First Quarter 2017 Business and Financial Results
finance.yahoo.com - May 11 at 5:17 PM
finance.yahoo.com logoOne Year Follow Up of Cytori Cell Therapy™ in Investigator Erectile Dysfunction Trial
finance.yahoo.com - May 10 at 4:49 PM
finance.yahoo.com logoCytori Therapeutics Announces Inducement Grants for New Employees
finance.yahoo.com - May 5 at 9:53 PM
americanbankingnews.com logoCytori Therapeutics (CYTX) Receives News Sentiment Rating of 0.35
www.americanbankingnews.com - May 3 at 1:24 PM
finance.yahoo.com logoCytori to Webcast First Quarter Financial Results on May 11
finance.yahoo.com - April 27 at 5:10 PM
americanbankingnews.com logoSomewhat Negative Press Coverage Somewhat Unlikely to Affect Cytori Therapeutics (CYTX) Share Price
www.americanbankingnews.com - April 24 at 2:01 PM
americanbankingnews.com logoCritical Media Coverage Very Unlikely to Impact Cytori Therapeutics (CYTX) Share Price
www.americanbankingnews.com - April 21 at 7:47 AM
americanbankingnews.com logoCytori Therapeutics (CYTX) Earns Media Impact Score of 0.29
www.americanbankingnews.com - April 18 at 1:54 PM
americanbankingnews.com logoCytori Therapeutics (CYTX) Getting Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 15 at 1:21 PM
streetinsider.com logoCytori Therapeutics (CYTX) IDE Approved by FDA for Pilot Clinical Trial to Evaluate Cytori Cell Therapy
www.streetinsider.com - April 11 at 12:56 PM
finance.yahoo.com logoCytori Therapeutics' stock plunges toward record low after stock offering prices at deep discount
finance.yahoo.com - April 11 at 12:56 PM
finance.yahoo.com logoCytori Therapeutics Stock Sliding on Offering Price Discount
finance.yahoo.com - April 11 at 12:56 PM
seekingalpha.com logoCytori Therapeutics -36% after pricing 8.6M-share offering at $1.10
seekingalpha.com - April 11 at 9:51 AM
finance.yahoo.com logoETFs with exposure to Cytori Therapeutics, Inc. : April 10, 2017
finance.yahoo.com - April 10 at 4:29 PM
finance.yahoo.com logoCytori Get FDA Approval for Clinical Burn Trial
finance.yahoo.com - April 10 at 4:29 PM
finance.yahoo.com logoCytori Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 10 at 4:29 PM
finance.yahoo.com logoCytori Receives U.S. FDA Approval for Burn Clinical Trial Related to BARDA Contract
finance.yahoo.com - April 10 at 12:03 PM
finance.yahoo.com logoCytori Rises on Crucial FDA Approval
finance.yahoo.com - April 10 at 12:03 PM
feeds.benzinga.com logoCytori Appoints Gregg Lapointe to Board of Directors
feeds.benzinga.com - April 3 at 7:50 AM
finance.yahoo.com logoCYTORI THERAPEUTICS, INC. Financials
finance.yahoo.com - March 30 at 5:05 PM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) Given a $10.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - March 27 at 12:57 AM
biz.yahoo.com logoCYTORI THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 24 at 9:55 PM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 24 at 11:39 AM
finance.yahoo.com logoCytori Reports Fourth Quarter and Full Year 2016 Business and Financial Results
finance.yahoo.com - March 23 at 5:11 PM
biz.yahoo.com logoCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
biz.yahoo.com - March 23 at 5:11 PM
finance.yahoo.com logoCytori reports 4Q loss
finance.yahoo.com - March 23 at 5:11 PM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - March 23 at 5:10 PM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) Receives Buy Rating from B. Riley
www.americanbankingnews.com - March 22 at 1:04 PM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:34 PM
finance.yahoo.com logoCytori to Webcast Fourth Quarter Financial Results on March 23rd
finance.yahoo.com - March 17 at 4:58 PM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 13 at 10:49 PM
biz.yahoo.com logoCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - March 3 at 9:46 PM
seekingalpha.com logoCytori Therapeutics Inc (CYTX)
seekingalpha.com - February 16 at 7:02 PM
streetinsider.com logoCytori Therapeutics, Inc. (CYTX) PT Raised to $10 at Maxim Group on Closure of the Azaya Deal - StreetInsider.com
www.streetinsider.com - February 16 at 2:00 PM
finance.yahoo.com logoCytori Completes Acquisition of Azaya Therapeutics Assets, Initiates Nanomedicine Program
finance.yahoo.com - February 16 at 2:00 PM
biz.yahoo.com logoCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o
biz.yahoo.com - February 16 at 2:00 PM
finance.yahoo.com logoCytori Provides Latest Corporate Update at the 2nd Annual Disruptive Growth & Healthcare Conference
finance.yahoo.com - February 14 at 5:30 PM

Social

Chart

Cytori Therapeutics (CYTX) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff